Shares of Kering (KER.FR), which is responsible for brands such as Gucci and Yves Saint Laurent, are down 5% today after Q1 results fell short of expectations. Gucci sales fell 25% in the first quarter. Efforts to revive Kering SA’s biggest brand have shown no signs of turning around amid a difficult period for the luxury goods industry.
“We believe 2025 will be another painful transition year for Gucci,” analysts at Cit wrote in a note. Remember, the brand accounts for almost 60% of the company’s total profits.
Selected Quarterly Results:
- Gucci like-for-like revenue -25%, estimated -23.6%
- Yves Saint Laurent like-for-like revenue -9%, estimated -8.03%
- Bottega Veneta like-for-like revenue +4%, estimated +7.71%
- Other Fashion Houses like-for-like revenue -11%, estimated -7.18%
- Eyewear and Corporate like-for-like revenue +3%, estimated +5.84%
- Revenue €3.88bn, -14% y/y, estimated €4.09bn
- Gucci revenue €1.57bn, -24% y/y, estimated €1.62bn
- Yves Saint Laurent revenue €679m, -8.2% y/y, estimated €690.7m EUR
- Bottega Veneta revenues EUR 405m, +4.4% y/y, estimated EUR 423.2m
- Other House revenues EUR 733m, -11% y/y, estimated EUR 775.8m
- Eyewear and corporate revenues EUR 558m, +4.1% y/y, estimated EUR 574.4m
Kering is “planning cautiously” for Q2 and continues to expect a double-digit revenue decline for the group; it still believes the second half of the year should be better than the first half.
Kering (KER.FR) shares are trading at their lowest levels since 2015. Source: xStation
Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price downđź’ˇ
DE40: Good earnings and cautious optimism
OpenAI announces an ambitious $1 trillion investment plan
LVMH surprises with its earnings. Is fashion back in favor with investorsâť“
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
